Complete allelic disruption of GSK-3 (α and β) induces AML

GSK-3β deletion transforms HSCs to a pre-neoplastic state reminiscent of human MDS

β-KO in HSCs disrupts Wnt/Akt/mTOR signaling while α-KO leads to metabolic changes

A molecular signature of GSK-3β-KO HSCs predicts clinical outcomes of MDS patients